BLA 103964 · Pharmaand Gmbh
Pegasys
Peginterferon Alfa-2a · Subcutaneous · Interferon alpha
NovelLast checked: Nov 20, 2026Latest source record: Dec 11, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Oct 16, 2002
Approved uses
10
Original approval plus efficacy supplements
Registered trials
517
140 Phase 3, 5 recruiting
FAERS reports
53,802
22,928 serious, 1,801 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS DISORDERS WARNING: RISK OF SERIOUS DISORDERS See full prescribing information for complete boxed warning. Risk of Serious Disorders May cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely and withdraw therapy with persistently severe or worsening signs or symptoms of the above disorders ( 5 ) Risk of Serious Disorders Alpha interferons, including PEGASYS (peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy [see Warnings...
What it is approved for
From the label in effect Oct 16, 2026.
PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC) ( 1.1 ) Adult Patients: In combination therapy with other hepatitis C virus drugs for adults with compensated liver disease. PEGASYS monotherapy is indicated only if patient has contraindication or significant intolerance to other HCV drugs. Pediatric Patients: In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease Chronic Hepatitis B (CHB) ( 1.2 ) Adult Patients: Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT) 1.1 Chronic Hepatitis C (CHC) Adult Patients: PEGASYS, as part of a combination regimen with other hepatitis C virus (HCV) antiviral drugs, is indicated for the treatment of adults with CHC and compensated liver disease. For information about the safe and effective use of other HCV antiviral drugs to be used in combination with PEGASYS, refer to their prescribing information. PEGASYS monotherapy is only indicated for the treatment of patients with CHC and compensated liver disease if there are contraindications or significant intolerance to other HCV antiviral drugs. Pediatric Patients: PEGASYS in combination with ribavirin is indicated for the treatment of pediatric patients 5 years of age and older with CHC and compensated liver disease. Limitations of Use : PEGASYS alone or in combination with ribavirin without additional HCV antiviral drugs is not recommended...
Mechanism: Pegylated recombinant human interferon alfa-2a is an inducer of the innate antiviral immune response [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 11, 2023 Supplement 5276 · Efficacy LabelMedication GuideLetter
- Oct 13, 2017 Supplement 5270 · Efficacy LabelLetter
- Sep 29, 2011 Supplement 5204 · Efficacy LabelLetter
- Aug 22, 2011 Supplement 5213 · Efficacy · priority review LabelLetter
- Aug 9, 2011 Supplement 5186 · Efficacy LabelLetter
- May 27, 2011 Supplement 5184 · Efficacy Label
- May 13, 2005 Supplement 5037 · Efficacy LabelLetter
- Feb 25, 2005 Supplement 5039 · Efficacy · priority review LabelLetter
- Dec 3, 2002 Supplement 5000 · Efficacy · priority review LetterLabel
- Oct 16, 2002 Original approval · Type 1 - New Molecular Entity NovelLabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
2 products under this application
- PEGASYS · PEGINTERFERON ALFA-2A 180U/5ML · SYRINGE, · Prescription
- PEGASYS · PEGINTERFERON ALFA-2A 180UG/VIAL · VIAL, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Peginterferon Alfa-2a" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionPivotal-lookingCompleted
Tanta UniversityAcademic, hospital or other
NCT02992457 · 10,000 participants · Start Jan 2015 · Primary completion Dec 2018
Drug: Sofosbuvir; Ribavirin and 6 more · For: Hepatitis C
Sites: Tanta, Egypt · 2 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00922779 · 6,661 participants · Start Jun 2002 · Primary completion Jun 2012
Drug: peginterferon alfa-2a [Pegasys]; ribavirin · For: Hepatitis C, Chronic
Sites: Arkhangelsk, Russia; Barnaul, Russia; Blagoveshchensk, Russia · 93 sites in all
- Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00081770 · 4,469 participants · Start Mar 2004 · Primary completion Nov 2007
Drug: PegIntron (peginterferon alfa-2b; SCH 54031); PegIntron (peginterferon alfa-2b; SCH 54031) and 3 more · For: Hepatitis C, Chronic
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00940420 · 2,695 participants · Start Oct 2002 · Primary completion Nov 2009
Drug: Copegus (ribavirin); Copegus (ribavirin) and 2 more · For: Hepatitis C, Chronic
Sites: Afula, Israel; Ashkelon, Israel; Bat Yam, Israel · 20 sites in all
- ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00077636 · 1,469 participants · Start Dec 2003 · Primary completion Mar 2006
Drug: Copegus; Copegus and 2 more · For: Hepatitis C, Chronic
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 132 sites in all
- Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive PatientsPivotal-lookingCompleted
Human Genome Sciences Inc.Industry
NCT00402428 · 1,331 participants · Start Dec 2006 · Primary completion Feb 2009
Drug: albumin interferon alfa-2b; peginterferon alfa-2a and 1 more · For: Chronic Hepatitis C
Sites: Birmingham, Alabama; Phoenix, Arizona; Fresno, California · 165 sites in all
- A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis CPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00394277 · 1,175 participants · Start Feb 2007 · Primary completion Apr 2009
Drug: peginterferon alfa-2a; Ribavirin and 2 more · For: Hepatitis C, Chronic
Sites: Birmingham, Alabama; Huntsville, Alabama; Anchorage, Alaska · 184 sites in all
- Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)Pivotal-lookingCompleted
Casa Sollievo della Sofferenza IRCCSAcademic, hospital or other
NCT01380938 · 1,150 participants · Start Dec 1, 2018 · Primary completion Nov 30, 2019
Drug: Peginterferon alpha-2a + Ribavirin · For: Chronic Hepatitis
Sites: Avellino, Italy; Bari, Italy; Barletta, Italy · 35 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue9,266
- nausea7,167
- anaemia6,637
- rash4,877
- headache4,456
- white blood cell count decreased4,232
- pruritus4,227
- pyrexia3,478
- diarrhoea3,388
- vomiting3,338
- asthenia3,152
- insomnia3,079
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 473 |
| 2005 | 1,118 |
| 2006 | 661 |
| 2007 | 655 |
| 2008 | 786 |
| 2009 | 971 |
| 2010 | 1,192 |
| 2011 | 1,492 |
| 2012 | 13,773 |
| 2013 | 8,523 |
| 2014 | 3,095 |
| 2015 | 17,300 |
| 2016 | 869 |
| 2017 | 546 |
| 2018 | 386 |
| 2019 | 326 |
| 2020 | 349 |
| 2021 | 249 |
| 2022 | 301 |
| 2023 | 194 |
| 2024 | 182 |
| 2025 | 213 |
| 2026 | 144 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Resolved · updated Aug 27, 2026
Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4).
Resolved · updated Aug 27, 2026
Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: PEGasys (PEGinterferon Alfa-2a)
2024 spending
$31.0M
Beneficiaries
1,095
8,086 claims
Per beneficiary
$28,327
$1,473.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $9,274,874 |
| 2023 | $25,889,832 |
| 2024 | $31,018,422 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.
Asselah T, Chulanov V, Lampertico P, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Multicenter Study
- Response-guided telaprevir combination treatment for hepatitis C virus infection.
Sherman KE, Flamm SL, Afdhal NH, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Randomized Controlled Trial
- Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.
Pavlovic V, Yang L, Chan HL, et al. · Antivir Ther 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment.
Aggarwal J, Vera-Llonch M, Donepudi M, et al. · J Viral Hepat 2015 · Clinical Trial, Phase III, Multicenter Study
- Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
Prati D, Shiffman ML, Diago M, et al. · J Hepatol 2006 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Review article: current antiviral therapy of chronic hepatitis B.
Ayoub WS, Keeffe EB · Aliment Pharmacol Ther 2011 · Systematic Review
Sponsor: Pharmaand Gmbh
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.